We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+32.2%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$2.52B
AUM Growth
+$1.12B
(+80%)
Cap. Flow
+$772M
Cap. Flow
% of AUM
30.59%
Top 10 Holdings %
Top 10 Hldgs %
26.22%
Holding
205
New
69
Increased
52
Reduced
26
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$62.5M |
| 2 |
Johnson & Johnson
JNJ
|
+$61M |
| 3 |
Fidelity National Information Services
FIS
|
+$54.2M |
| 4 |
KLA
KLAC
|
+$44.1M |
| 5 |
PayPal
PYPL
|
+$41.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$65.7M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$46.8M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$46.5M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$41.2M |
| 5 |
Analog Devices
ADI
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.91% |
| 2 | Technology | 35.52% |
| 3 | Communication Services | 5.66% |
| 4 | Consumer Discretionary | 4.26% |
| 5 | Industrials | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EXAS
126
DELISTED
Exact Sciences
EXAS
| $3.08M | 0.12% |
+35,432
| New | +$2.83M |
|
127
Cinemark Holdings
CNK
$4.42B
| $3.06M | 0.12% |
264,597
-123,246
| -32% | -$1.67M |
|
128
Acadia Pharmaceuticals
ACAD
$4.41B
| $2.98M | 0.12% |
+61,575
| New | +$2.96M |
|
129
Warner Music
WMG
$13.4B
| $2.95M | 0.12% |
+100,000
| New | +$3.12M |
|
|
MNTA
130
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $2.79M | 0.11% |
83,947
-114,920
| -58% | -$3.66M |
|
|
AFMD
131
DELISTED
Affimed
AFMD
| $2.67M | 0.11% |
57,960
+10,756
| +23% | +$299K |
|
|
CHMA
132
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $2.26M | 0.09% |
419,736
-149,608
| -26% | -$824K |
|
133
Zentalis Pharmaceuticals
ZNTL
$343M
| $2.1M | 0.08% |
+43,726
| New | +$1.68M |
|
|
FUSN
134
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $2.1M | 0.08% |
+120,000
| New | +$2.09M |
|
135
Bruker
BRKR
$9.68B
| $1.86M | 0.07% |
+45,647
| New | +$1.8M |
|
|
ORTX
136
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $1.75M | 0.07% |
29,225
-29,900
| -51% | -$2.74M |
|
137
Maximus
MMS
$3.24B
| $1.44M | 0.06% |
+20,403
| New | +$1.37M |
|
138
Envista
NVST
$4.45B
| $1.06M | 0.04% |
+50,115
| New | +$939K |
|
139
Savara
SVRA
$1.11B
| $917K | 0.04% |
368,420
+19,474
| +6% | +$47.4K |
|
140
Cencora
COR
$60.3B
| $890K | 0.04% |
8,830
-137,177
| -94% | -$12.6M |
|
|
API
141
Agora
API
$342M
| $729K | 0.03% |
+16,495
| New | +$779K |
|
142
Vaxcyte
PCVX
$7.81B
| $728K | 0.03% |
+23,026
| New | +$740K |
|
|
NARI
143
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $650K | 0.03% |
+13,409
| New | +$640K |
|
|
PRAH
144
DELISTED
PRA Health Sciences, Inc.
PRAH
| $543K | 0.02% |
+5,582
| New | +$519K |
|
|
INFN
145
DELISTED
Infinera Corporation Common Stock
INFN
| $521K | 0.02% |
88,054
-179,910
| -67% | -$986K |
|
146
HealthEquity
HQY
$8.69B
| $358K | 0.01% |
+6,100
| New | +$337K |
|
|
AMTI
147
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $276K | 0.01% |
+10,993
| New | +$278K |
|
148
Apple
AAPL
$4.47T
| – | – |
-216,108
| Closed | -$13.7M |
|
149
Abbott
ABT
$184B
| – | – |
-120,616
| Closed | -$9.52M |
|
|
AMRN
150
Amarin Corp
AMRN
$290M
| – | – |
-22,562
| Closed | -$1.8M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Woodline Partners held 205 positions worth $2.52B, up 80% from $1.4B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Woodline Partners deployed $772M of net new capital in Q2 2020, opening 69 new positions and adding to 52 existing holdings. Its largest new stake was Johnson & Johnson: 418,880 shares worth $58.9M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 46% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Immunomedics Inc, an estimated $41.2M trimmed.
- Woodline Partners's largest Q2 2020 buy was Johnson & Johnson: 418,880 shares worth $58.9M.
- Woodline Partners added most to Intel in Q2 2020, an estimated $62.5M increase.
- Woodline Partners's biggest Q2 2020 reduction was Immunomedics Inc, cutting an estimated $41.2M.
- Woodline Partners fully exited Pfizer in Q2 2020, selling an estimated $65.7M.
- Woodline Partners's ten largest holdings make up 26% of its $2.52B portfolio in Q2 2020.
- Woodline Partners opened 69 new positions and closed 58 in Q2 2020.
- Woodline Partners's portfolio value rose 80% quarter-over-quarter to $2.52B.
Based on Woodline Partners's 13F filing for Q2 2020, filed 14 Aug 2020.